Citations
1 publicationsPublications from researchers using this productDescription
STAT3-IN-1 is a potent, selective, and orally active inhibitor of STAT3 with IC50 values of 1.82μM and 2.14μM in HT29 and MDA-MB-231 cells, respectively [1]. STAT3-IN-1 inhibits both STAT3 acetylation and phosphorylation, leading to increased NKG2D ligand expression and decreased IL-10 levels[1-2]. STAT3-IN-1 has been widely used to induce growth arrest and tumor cell death in Meta4 organoids[3].
In vitro, STAT3-IN-1 treatment at 1μM for 8h significantly inhibited the decrease in Nos2 mRNA levels and the increase in IL-1β and IL-6 levels caused by 100μg/ml zymosan in mouse primary bone marrow dendritic cells (BMDCs)[4]. STAT3-IN-1 treatment (3μM) for 48h suppressed the cell migration of DU145 cells induced by CCL5 and retarded the upregulation of Snail and TWIST[5].
In vivo, STAT3-IN-1 treatment via oral administration at a dose of 20mg/kg daily for 14 days significantly inhibited tumor growth in a xenograft model of 4T1 cells without affecting body weight[6]. Injecting STAT3-IN-1 (5mg/kg) and temozolomide (5mg/kg) intratumorally every 5 days for 10 consecutive days can significantly inhibit the tumor growth of A375 cell-xenograft mice with overexpressed RPL18 and improve the survival rate[7].
References:
[1] Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery[J]. Journal of Experimental & Clinical Cancer Research, 2024, 43(1): 23.
[2] Jia Z, Xiao B, Li J, et al. BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells[J]. Anti-Cancer Drugs, 2025, 36(5): 374-382.
[3] Kim H, Jang B, Zhang C, et al. Targeting stem cells and dysplastic features with dual MEK/ERK and STAT3 suppression in gastric carcinogenesis[J]. Gastroenterology, 2024, 166(1): 117-131.
[4] Wu H, Yin X, Zhao X, et al. HDAC11 negatively regulates antifungal immunity by inhibiting Nos2 expression via binding with transcriptional repressor STAT3[J]. Redox Biology, 2022, 56: 102461.
[5] Ma J, Shayiti F, Ma J, et al. Tumor‐associated macrophage‐derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer[J]. Cell biology international, 2021, 45(10): 2054-2062.
[6] Li S, Zhang W, Yang Y, et al. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein[J]. European journal of medicinal chemistry, 2016, 124: 1006-1018.
[7] Zuo C, Hu C, Jiang X, et al. RPL18 promotes melanoma progression and drug resistance via BTF3/STAT3-dependent mechanisms and immune modulation[J]. iScience, 2026, 29(1).
Protocol
| Cell experiment [1]: | |
Cell lines | DU145 cells |
Preparation Method | DU145 cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS) at 37℃ in the presence of 5% CO2. Cells migrating assay was detected using 8-μm trans-well chambers. DU145 cells were pretreated with STAT3-IN-1 (3μM) and CCL5 (100ng/ml) for 48h. 5×104 cells in 150μl non-serum culture medium were seeded into the upper chambers. A total of 800μl culture medium containing 10% FBS medium was added into the lower chambers. Twenty-four hours later, trans-wells were washed with phosphate-buffered saline (PBS), fixed with formalin, and stained with 0.1% crystal violet. Cells were counted in three random fields per well under a ×100 microscope. |
Reaction Conditions | 3μM; 48h |
Applications | STAT3-IN-1 treatment suppressed the cell migration of DU145 cells induced by CCL5. |
| Animal experiment [2]: | |
Animal models | Female Kunming mice |
Preparation Method | Adult female Kunming mice (4-6 weeks of age) were group-housed in polysulfone cages with bedding material, and were housed in a room with controlled humidity (50±10%) and temperature (25±3°C) under a 12/12h light/dark cycle. All mice were adaptively fed for one week. Freshly harvested breast cancer cells 4T1 (2.5×106 cells per mouse, resuspended in 100μl PBS) were injected into the armpit of the mice. The mice were given 20mg/kg STAT3-IN-1, or vehicle p.o. once daily. Body weights were measured every other day. On the 14th day, all mice were killed, and the tumor was segregated and weighed. |
Dosage form | 20mg/kg/day for 14 days; p.o. |
Applications | STAT3-IN-1 treatment inhibited tumor growth in a xenograft model of 4T1 cells without affecting body weight. |
References: | |
Product Documents
Chemical Properties
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
Reviews
Review for STAT3-IN-1
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
